The results demonstrate that LAS, a SERM without any demonstrable SERD activity, has clear advantages over FUL, the only clinically approved SERD, at inhibiting primary tumor growth and metastasis in ER+ breast cancer mouse xenografts expressing Y537S and D538G ERα mutants. The gene discussed is ESR1; the disease is breast cancer.